Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FX-322 in Adults Undergoing Cochlear Implantation
NCT03300687Phase 1Completed
- Sponsor
- Frequency Therapeutics
- Start
- May 2017
- Primary completion
- Dec 2017
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of FX-322 in sensorineural hearing loss (SNHL) (2 arms), sponsored by Frequency Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events up to 2 weeks. Started May 2017; status: completed.
02
Drugs
FX-322
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT03300687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03300687.